Immuno-oncology is the study and development of treatments that take advantage of the body’s immune system to fight cancer. Promising clinical results from this approach in multiple indications have energized research in this area and led to regulatory approvals of multiple immune-therapies. The promise of this class of cancer treatments has also prompted statisticians to dive deeper into important statistical issues associated with the design and evaluation of these therapies. Issues of particular interest include pseudoprogression, dose optimization, combination therapies, and non-proportional hazards. This meet-up will focus on some of these statistical issues and discuss opportunities that have arisen for statisticians.
The format used for these meet-ups is two 20 minute talks followed by a panel discussion in which a moderator gives some of their own perspective and then asks questions of the speakers, some of their own and some of the ones submitted by the audience via the chat tool.
This is the fifth NISS-Merck Meet-up, the first one this year!
The agenda for the meet-up is as follows:
Welcome (Dan Holder, Merck)
Quantifying the long-term treatment benefit with cancer immunotherapies (Bo Huang, Pfizer)
Some Adaptive Design Options for Late Stage Development of Oncology Immunotherapies (Cong Chen, Merck)
Moderated by Andrew Stone, (Stone Biostatistics). Panelists are Cong Chen and Bo Huang.